Sign In

Friday, March 22, 2019 - 8:00 am to Saturday, March 23, 2019 - 3:30 pm
Add to Calendar

Course Description / Need Statement

The Emerging Trends Conference will provide the opportunity for attendees to learn more about and improve upon their selection of precise therapy for patients with hepatocellular carcinoma. Also, attendees will increase their knowledge regarding design, implementation and participation in HCC clinical trials with an enhanced ability to assess the efficacy of treatment using a variety of response criteria.

Program Chairs

  • Josep M. Llovet, MD, PhD, FAASLD
  • Lewis R. Roberts, MBChB, PhD, FAASLD

Location

  • The Westin Buckhead Atlanta
    Atlanta, GA

Learning Objectives

  • Review novel strategies for biomarker based clinical trial designs and articulate new approaches including the role of tumor biopsies and circulating cell-free based assays in guiding therapeutic decision-making.
  • Understand recent advances in integrated molecular classification of HCC and their application to improved treatment of HCC.
  • Review recently approved molecular therapies and anticipated novel immune-based, cellular, and oncolytic virus therapies for HCC and effectively manage the common side effects of these therapies.

Core Competencies

  • Patient Care and Procedural Skills
  • Medical Knowledge Practice-based Learning and Improvement
  • Systems-based Practice
  • Provide Patient-centered Care
  • Work in Interdisciplinary Teams
  • Roles/Responsibilities Interprofessional Communication
  • Apply Quality Improvement
  • Teams and Teamwork Utilize Informatics

Continuing Education

  • CME – 9.00 AMA PRA Category 1 Credits™

Target Audience

  • Hepatologists
  • Oncologist
  • Radiologist
  • Nurses
  • Nurse Practitioners
  • Pharmacists
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Government/Regulatory Representatives
  • Industry

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7:00 am ET both days.

Friday, March 22 -- Session I

Session I: Overview of End-Points and New Trial Designs in Cancer
Moderators: Lewis R. Roberts, MBChB, PhD, FAASLD and Jordi Bruix, MD

  • 8:00 am – 8:05 am
    Introduction and Scope of the Emerging Topic Conference
    Lewis R. Roberts, MBChB, PhD, FAASLD and Josep M. Llovet, MD, FAASLD
  • 8:05 am – 8:25 am
    Current HCC Molecular Classification
    David Wheeler, PhD
  • 8:25 am – 8:45 am
    Cancer Clinical Trials: A View from the FDA
    Richard Pazdur, MD
  • 8:45 am – 9:05 am
    Clinical Trial Designs Incorporating Predictive Biomarkers
    Lindsay A. Renfro, PhD
  • 9:05 am – 9:25 am
    Staging and Design Considerations in HCC Trials
    Jordi Bruix, MD
  • 9:25 am – 9:40 am
    Panel Discussion / Q&A
  • 9:40 am – 10:00 am
    Break

Friday, March 22 -- Session II

Session II: Design and End-Points in Trials for HCC
Moderators: Josep M. Llovet, MD, FAASLD and Peter R. Galle, MD

  • 10:00 am – 10:20 am
    Neo-Adjuvant and Adjuvant Trials
    Peter R. Galle, MD
  • 10:20 am – 10:40 am
    Next Steps in Intermediate Stage HCC
    Laura Kulik, MD
  • 10:40 am – 11:00 am
    Advanced HCC, First, Second Line and Beyond
    Josep M. Llovet, MD, FAASLD
  • 11:00 am – 11:20 am
    Radiologic Assessment of Response
    Riccardo Lencioni, MD
  • 11:20 am – 11:40 am
    Panel Discussion / Q&A
  • 11:45 am – 1:15 pm
    Lunch and Poster Session

Friday, March 22 -- Session III

Session III: Incorporating Immune Therapies into Trial Designs
Moderators: Anthony B. El-Kouiery, MD and Mitesh Borad, MD

  • 1:15 pm – 1:35 pm
    Checkpoint Inhibitors and Related Strategies
    Anthony B. El-Kouiery, MD
  • 1:35 pm – 1:55 pm
    Oncolytic and Immunovirotherapy
    Mitesh Borad, MD
  • 1:55 pm – 2:15 pm
    Is there a Role for CAR-T and Cell Therapies in HCC?
    Tim Greten, MD
  • 2:15 pm – 2:35 pm
    Panel Discussion / Q&A
  • 2:35 pm – 2:55 pm
    Break

Friday, March 22 -- Session IV

Session IV: Emerging Topics in Trial Design
Moderators: Tim Greten, MD and David R. Grant, MD

  • 2:55 pm – 3:15 pm
    Design of Clinical Trials in the Setting of Liver Transplantation
    David R. Grant, MD
  • 3:15 pm – 3:35 pm
    Recent Results from Phase II-III Studies Testing SBRT (Stereotactic Body Radiation)
    Ted S. Hong, MD
  • 3:35 pm – 3:55 pm
    Tumor Biopsy in Trials for Advanced HCC
    Lorenza Rimassa, MD
  • 3:55 pm – 4:15 pm
    What Really Counts: Optimizing Quality of Life
    Neehar Parikh, MD
  • 4:15 pm – 4:30 pm
    Panel Discussion / Q&A

Saturday, March 23 -- Session V

Session V: Assessing Predictions of Response and Therapies
Moderators: Richard Finn, MD and Maria Reig, MD

  • 8:00 am – 8:20 am
    Side Effect Response in Assessing Efficacy
    Maria Reig, MD
  • 8:20 am – 8:40 am
    Biomarker Response in Assessing Efficacy
    Richard Finn, MD
  • 8:40 am – 9:00 am
    Liquid Biopsy Diagnosis, Prognosis & Prediction
    Kang Zhang, MD, PhD
  • 9:00 am – 9:20 am
    Panel Discussion / Q&A
  • 9:20 am – 9:40 am
    Break

Saturday, March 23 -- Session VI

Session VI: Novel Concepts and Challenges
Moderators: Neehar Parikh, MD and Andrew X. Zhu, MD, PhD

  • 9:40 am – 10:00 am
    The View from Industry
    Gerold Meinhardt, MD
  • 10:00 am – 10:20 am
    Challenges in Trial Design in HCC and How to Solve Them
    Andrew X. Zhu, MD, PhD
  • 10:20 am – 10:40 am
    Panel Discussion / Q&A
  • 10:40 am – 11:00 am
    Wrap-up
    Lewis R. Roberts, MBChB, PhD, FAASLD
  • 11:00 am
    Adjourn